Literature DB >> 19520197

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.

Sonya J Snedecor1, David R Strutton, Vincent Ciuryla, Elissa J Schwartz, Marc F Botteman.   

Abstract

We developed an age-structured, transmission-dynamic, mathematical model to quantify the direct and indirect benefits of infant PCV7 vaccination. The model simulates the acquisition of asymptomatic carriage of Streptococcus pneumoniae and the development of fatal and non-fatal invasive pneumococcal disease (IPD) among vaccinated and unvaccinated individuals aged <2, 2-4, 5-17, 18-49, 50-64, and >or=65 years old. The model was parameterized using published US surveillance data, supplemented with data from published literature. The model predicts the observed incidence of IPD with good agreement and may be used to predict the impact of various vaccination strategies in the US or other populations yet to introduce PCV7.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520197     DOI: 10.1016/j.vaccine.2009.05.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  A systematic review of health economic evaluations of vaccines in Brazil.

Authors:  Ana Marli Christovam Sartori; Luciana Martins Rozman; Tassia Cristina Decimoni; Roseli Leandro; Hillegonda Maria Dutilh Novaes; Patrícia Coelho de Soárez
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

2.  Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Authors:  Alessia Melegaro; Yoon Hong Choi; Robert George; W John Edmunds; Elizabeth Miller; Nigel J Gay
Journal:  BMC Infect Dis       Date:  2010-04-08       Impact factor: 3.090

3.  Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.

Authors:  Jaime E Ordóñez; John J Orozco
Journal:  BMC Infect Dis       Date:  2014-03-28       Impact factor: 3.090

4.  Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

Authors:  Jorge A Gomez; Javier Nieto Guevara; Josefina C Carlos; Joanne A de Castro; Donald Ray Josue; Edwin Rodriguez
Journal:  Infect Dis Ther       Date:  2022-05-16

5.  Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model.

Authors:  Roberto Pradas; Angel Gil de Miguel; Alejandro Álvaro; Ruth Gil-Prieto; Reyes Lorente; Cristina Méndez; Pablo Guijarro; Fernando Antoñanzas
Journal:  BMC Infect Dis       Date:  2013-04-11       Impact factor: 3.090

6.  Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis.

Authors:  Simone M C Spoorenberg; Willem Jan W Bos; Rik Heijligenberg; Paul G P Voorn; Jan C Grutters; Ger T Rijkers; Ewoudt M W van de Garde
Journal:  BMC Infect Dis       Date:  2014-06-17       Impact factor: 3.090

7.  Long-term effects of penicillin resistance and fitness cost on pneumococcal transmission dynamics in a developed setting.

Authors:  Diana Tilevik
Journal:  Infect Ecol Epidemiol       Date:  2016-05-19

8.  Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".

Authors:  Jorge A Gómez; Thatiana de Jesus Pereira Pinto; Javier Nieto Guevara; Tatiana Guimarães de Noronha
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 3.452

9.  Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK.

Authors:  M Wasserman; A Lucas; D Jones; M Wilson; B Hilton; A Vyse; H Madhava; A Brogan; M Slack; R Farkouh
Journal:  Epidemiol Infect       Date:  2018-07-17       Impact factor: 4.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.